Zealand Pharma — Director's Dealing 2013

Sep 16, 2013

Copenhagen, 2013-09-16 10:14 CEST (GLOBE NEWSWIRE) --

Report of insider transactions
No. 04/2013

Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S
(“Zealand”) shall announce transactions in the company’s shares and related
securities by executives and persons/companies closely related to them.

In this regard, Zealand announces the following transaction:

Name: David H. Solomon

Reason: President and Chief Executive Officer

Issuer: Zealand Pharma A/S

Type Shares

ISIN code: DK0060257814

Transaction: Purchase

Trading date: 12 September 2013

Market: NASDAQ OMX København A/S

Amount: 10,000

Price: DKK 64.00

Market value: DKK 640,000.00

Hereafter, David H. Solomon owns 30,600 shares and 387,150 warrants in Zealand.

                                  ***

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand PharmaZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL)
(“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand
specializes in the discovery, optimization and development of novel peptide
drugs and has a broad and mature pipeline of drug candidates identified through
its own drug discovery activities. The company’s focus lies in the field of
cardio-metabolic diseases, diabetes and obesity in particular, and its lead
drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is
licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide
(marketed by Sanofi as Lyxumia®) is approved in Europe and Japan and under
regulatory review in a number of other countries globally. In the U.S., an NDA
is planned to be submitted in 2015, after completion of the ELIXA CV outcome
study.

Zealand has a partnering strategy for the development and commercialization of
its products and in addition to the license agreement with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in
chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: www.zealandpharma.com.

@ZealandPharma